NEW YORK, May 14, 2010 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq:NBI...
- Easy-to-swallow formulation provides important new alternative for patients RESEARCH TRIANGLE PARK, N.C., May 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) announced today that the...
FRAZER, Pa. and PHILADELPHIA, Nov. 26 /PRNewswire-FirstCall/ -- Cephalon, Inc. (NASDAQ:CEPH) and Eurand, Inc. (NASDAQ:EURX) today announced that they have filed a lawsuit in U.S. District Court...
FRAZER, Pa. and PHILADELPHIA, Oct. 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (NASDAQ:CEPH) and Eurand NV (NASDAQ:EURX) today announced receipt of a Paragraph IV Certification Notice Letter on...
AMSTERDAM, Netherlands, Nov. 12 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based...
MILAN, Italy, Sept. 4 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a global specialty pharmaceutical company, announced today that GlaxoSmithKline (NYSE:GSK), working in collaboration...
Eurand Invites Public to Listen to Webcast MILAN, Italy, Aug. 24 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and...
MILAN, Italy and DAYTON, Ohio, Aug. 23 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), announced today that Cephalon, Inc. (NASDAQ:CEPH) has signed an agreement to acquire Amrix(R) from ECR...
Adjudication Panel Praises Innovative Approaches to Improving Bioavailability of Drugs MILAN, Italy, Aug. 9 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX) and the Controlled Release Society...
AMSTERDAM, Netherlands, Aug. 6 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관